Patent · US Active

2-[1H-benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors

US8129396B2 · kind B2 · utility

0Cited by

0References

21Claims

0Family size

Assignee

Telik, Inc. · US

Inventors

Natalia Aurrecoechea · Oakland, US
Paul Powell Beroza · Belmont, US
Komath V. Damodaran · Cupertino, US
Karen Y. Pontius · Aromas, US
Louise Robinson · Redwood City, US
Reyna J. Simon · Los Gatos, US
Truong Vu · San Martin, US
Kevin T. Weber · Fremont, US

Key dates

Filing date	Sep 25, 2009
Grant date	Mar 6, 2012
Priority date	—
Expiry date	Nov 7, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D417/14
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

2-[1H-benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and their salts are kinase inhibitors, useful in the treatment of cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.